Original Article

Primary coronary angioplasty in patients over 80 years of age

Alan Castro D'Avila^a, Renato Roese Filho^a, Marcia Moura Schmidt^a, Karina Melleu^b, Cristiano de Oliveira Cardoso^a, Carlos Antonio Mascia Gottschall^a, Alexandre Schann de Quadros^{a,*}, Alexandre Damiani Azmus^a

- ^a Instituto de Cardiologia/Fundação Universitária de Cardiologia, Porto Alegre, RS, Brazil
- ^b Universidade Luterana do Brasil, Canoas, RS, Brazil

ARTICLE INFO

Article history: Received 10 August 2015 Accepted 25 November 2015

Keywords: Angioplasty Myocardial infarction Elderly

ABSTRACT

Background: The number of elderly patients submitted to primary percutaneous coronary intervention (PCI) is increasingly prevalent. Historically, this population has a worse prognosis when compared to the younger ones. This study aimed to compare the characteristics and 30-day clinical outcomes of patients aged \geq 80 years to those < 80 years submitted to primary PCI.

Methods: Observational, prospective cohort study, extracted from the database of Instituto de Cardiologia do Rio Grande do Sul, between 2009 and 2013.

Results: A total of 1,970 patients were included, of whom 122 (6.2%) were aged \geq 80 years. The elderly showed a predominance of the female gender (50% vs. 29%; p < 0.001), diabetes (34.4% vs. 23.2%; p = 0.004), Killip class 3 or 4 (13.1% vs. 7.4%; p < 0.02), and longer door-to-balloon time (1.4 hour [1.0-1.9 hour] vs. 1.1 hour [0.8-1.5 hour]; p < 0.001). The TIMI 3 post flow did not show any difference between the groups (86% vs. 90.7%; p = 0.08), but the Blush 3 post was lower (59.3% vs. 70.9%; p = 0.01) in the elderly. Angiographic success was obtained in 92.0% vs. 95.6%; p = 0.07. Temporary pacemakers, severe arrhythmias, and aborted sudden death were more frequently observed in patients aged \geq 80 years. The rates of major adverse cardiovascular events and death at 30 days were higher in the older group (32.2% vs. 11.5% and 29.7% vs. 7.2%; p < 0.001).

Conclusions: In this contemporary analysis, patients aged ≥ 80 years undergoing primary PCI had a more severe clinical and angiographic profile, longer door-to-balloon time, lower final Blush 3, with higher rates of hospital complications and 30-day mortality when compared with younger patients.

© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Angioplastia coronariana primária em pacientes com mais de 80 anos

RESUMO

Palavras-chave: Angioplastia Infarto do miocárdio Idoso Introdução: É cada vez mais prevalente o número de idosos submetidos à intervenção coronariana percutânea primária (ICPp). Historicamente, essa população apresenta pior prognóstico quando comparada aos mais jovens. Nosso objetivo foi comparar as características e os desfechos clínicos em 30 dias de pacientes ≥ 80 anos aos < 80 anos submetidos à ICPp.

Métodos: Estudo de coorte observacional, prospectivo, extraído do banco de dados do Instituto de Cardiologia do Rio Grande do Sul, entre 2009 e 2013.

Resultados: Foram incluídos 1.970 pacientes, sendo 122 (6,2%) com idade ≥ 80 anos. Os mais idosos mostraram predomínio do sexo feminino (50% vs. 29%; p < 0.001), diabetes (34,4% vs. 23,2%; p = 0.004), classe Killip 3 ou 4 (13,1% vs. 7,4%; p = 0.02) e tempo porta-balão superior (1,4 hora [1,0-1,9 hora] vs. 1,1 hora [0,8-1,5 hora]; p < 0.001). O fluxo TIMI 3 pós não mostrou diferença entre os grupos (86% vs. 90,7%; p = 0.08), mas o Blush 3 pós foi menor (59,3% vs. 70,9%; p = 0.01) nos idosos. O sucesso angiográfico foi obtido em 92,0% vs. 95,6%; p = 0.07. Necessidade de marca-passo provisório, arritmias graves e morte súbita abortada foram mais frequentes nos pacientes ≥ 80 anos. Taxas de eventos cardiovasculares adversos maiores e óbito em 30 dias foram mais frequentes no grupo mais idoso (32,2% vs. 11,5% e 29,7% vs. 7,2%; p < 0.001).

Conclusões: Nesta análise contemporânea, pacientes ≥ 80 anos submetidos à ICPp apresentaram perfil clínico e angiográfico mais grave, tempo porta-balão mais prolongado, menor Blush 3 final, com maiores taxas de complicações hospitalares e mortalidade em 30 dias, quando comparados aos pacientes mais jovens.

© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of original article: http://dx.doi.org/10.1016/j.rbci.2016.12.004

^{*} Corresponding author: Instituto de Cardiologia/Fundação Universitária de Cardiologia, Av. Princesa Isabel, 395, Santana, CEP, 90620-001, Porto Alegre, RS, Brasil. E-mail: alesq@terra.com.br (A.S. de Quadros).

Peer review under the responsibility of Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista.

Introduction

The strategy of mechanical recanalization has been preferred to the use of thrombolytics, especially in the elderly subgroup, as they have increased bleeding rates. Registries of patients with acute myocardial infarction (AMI) treated with mechanical recanalization show an increasing number of patients who are elderly or aged ≥ 80 years.^{1,2}

This subgroup may have an atypical presentation, including silent or unrecognized AMI, or left bundle branch block (LBBB) as an electrocardiographic presentation.³ Additionally, cognitive problems may delay the identification of the clinical picture.

Patients older than 80 years have a two- to three-fold increased risk of cardiogenic shock, heart failure, and atrial fibrillation during hospitalization.⁴ Killip class ≥ 2 and acute heart failure are much more common in patients aged ≥ 85 years.^{4,5} The in-hospital mortality of octogenarians is three-fold higher and, in nonagenarians, four-fold higher than in younger patients with ST-segment elevation AMI (STEMI).⁴

This study aimed to increase the known evidence, contributing to a national database, as the evidence for this age group is scarce, as elderly patients are usually excluded from the large clinical trials. The data is limited to observational studies, which hinders the assessment of the results of procedures and drug therapy applied to them.^{3,6}

Thus, the objective of this study was to compare the clinical, angiographic, and procedure characteristics, as well as clinical outcomes of patients with STEMI aged \geq 80 years with those aged < 80 years, submitted to primary percutaneous coronary intervention (PCI) at this institution.

Methods

This was a single-center, prospective cohort study that included all patients with STEMI submitted to primary PCI at Instituto de Cardiologia do Rio Grande do Sul, from December 2009 to December 2013. All enrolled patients signed the Informed Consent Form, and the study was approved by the institution's Ethics Committee.

Population

Sequential patients with STEMI admitted to this institution and referred to primary PCI were considered for inclusion in the study. STEMI was defined as chest pain at rest lasting more than 30 minutes associated with ST-segment elevation > 1 mm in two or more contiguous leads of the electrocardiogram, or new LBBB. Exclusion criteria were chest pain lasting more than 12 hours and patient refusal to participate in the study.

The primary PCI was performed as recommended in the literature. All patients were medicated on admission with 300 mg of acetylsalicylic acid and 300 to 600 mg of clopidogrel, 60 mg of prasugrel, or 180 mg of ticagrelor. Unfractionated heparin (60 to 100 U/kg) was administered prior to the primary PCI. Technical aspects of the procedure, such as type and number of stents, use of adjunctive devices, and use of glycoprotein IIb/IIIa inhibitors were at the discretion of the interventionist responsible for the primary PCI.

Blood collection for laboratory analysis was performed in the emergency room prior to referral to the primary PCI.

Statistical analysis

Qualitative variables were described as absolute and relative frequencies, and compared with the Chi-squared test. Continuous variables were expressed as mean \pm standard deviation and compared with the unpaired Student's t test. Continuous variables with

non-normal distribution were shown as median and interquartile range, and compared with the Mann-Whitney test.

The data were collected in a Microsoft Access database, and statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) for Windows, version 17.0. Statistical significance was defined as a two-tailed p-value ≤ 0.05 .

Results

A total of 1,970 consecutive patients with STEMI were included, of whom 122 (6.2%) were aged \geq 80 years. The mean age was 84.5 \pm 4.4 years and 58.7 \pm 10.3 years; the elderly showed a predominance of the female gender (50% vs. 29%; p < 0.001), diabetes (34.4% vs. 23.2%; p = 0.004); conditions such as renal failure and chronic obstructive pulmonary disease, in addition to a lower number of smokers (Table 1).

LBBB or complete atrioventricular block (CAVB) were significantly more frequent in the elderly, as was the clinical presentation in Killip 3 or 4 functional class (13.1% vs. 7.4%; p = 0.02). Door-to-balloon time was longer in patients aged ≥ 80 years (1.4 hour [1.0-1.9 hour] vs. 1.1 hour [0.8-1.5 hour]; p < 0.001).

The patients' angiographic profile was very similar between the groups, with the same number of patients with triple-vessel disease (20.5% vs. 18.6%; p = 0.33), but a lower ejection fraction in the group aged ≥ 80 years (39.7 \pm 18.5% vs. 54.5 \pm 16.0%; p = 0.008; Table 2).

Regarding the procedure, femoral access was more often used (82.4% vs. 62.3%, p < 0.001), and glycoprotein IIb/IIIa inhibitors and 600 mg clopidogrel were less used in patients older than 80 years. Pre-dilation was used more frequently in the elderly, and -Thrombolysis in Myocardial Infarction (TIMI) 3 flow post-procedure showed no difference between the groups (86% vs. 90.7%; p = 0.08), but post-Blush 3 was significantly lower in the patients aged \geq 80 years (59.3% vs. 70.8%; p = 0.01). Angiographic success was achieved in 92.0% vs. 95.6% (p = 0.07).

The laboratory characteristics are shown in Table 3. Markers of myocardial injury, such high-sensitivity troponin T (2,776 IU/L [712-7,853 IU/L] vs. 2,417 IU/L [641-5,915 IU/L]; p = 0.10) and creatine kinase MB isoenzyme (CK-MB; 43.0 IU/L [16.7-83.7 IU/L] vs. 40.5 IU/L [17.0-81.0 IU/L]; p = 0.66) were similar between the groups.

Patients aged \geq 80 years more often required a temporary pace-maker (11.8% vs. 4.5%; p < 0.001) during hospitalization and also showed significantly higher rates of severe arrhythmias or aborted sudden death (20.3% vs. 7.2%; p < 0.001). Respiratory dysfunction requiring mechanical ventilation (18.6% vs. 7.3%; p < 0.001) and acute renal failure (11.0% vs. 3.5%; p < 0.001) were more prevalent in this group of patients.

The rates of combined major cardiovascular events and death at 30 days were statistically more frequent in the group aged \geq 80 years (32.2% vs. 11.5% and 29.7% vs. 7.2%; p < 0.001). Complications such as stroke, reinfarction, and stent thrombosis were not different between the groups (Table 4).

Discussion

The in-hospital evolution of patients aged \geq 80 years was definitely less favorable in Brazil, with very high rates of mortality and complication. This result was observed regardless of the high rate of angiographic success.

Several registries have shown that advanced age is an independent factor for in-hospital mortality, together with hemodynamic instability, chronic kidney disease (CKD), diabetes, and multi-vessel disease.⁸⁻¹⁰ This result can be even worse when an nonagenarian is compared with a octogenarian patient.^{11,12}

Table 1Baseline clinical characteristics.

Characteristics	≥ 80 years	< 80 years	<i>p</i> -value
	(n = 122)	(n = 1,848)	·
Age, years	84.5 ± 4.4	58.7 ± 10.3	< 0.001
Male gender, n (%)	61 (50.0)	1.313 (71.0)	< 0.001
White, n (%)	107 (93.9)	1.555 (86.7)	0.13
Arterial hypertension, n (%)	85 (69.7)	1.188 (64.3)	0.19
Diabetes mellitus, n (%)	42 (34.4)	428 (23.2)	0.004
Dyslipidemia, n (%)	34 (27.9)	667 (36.1)	0.07
Smoking, n (%)	6 (5.0)	817 (44.3)	< 0.001
Family history of CAD, n (%)	19 (15.8)	581 (31.4)	< 0.001
Anterior AMI, n (%)	53 (43.4)	800 (43.3)	0.97
Right ventricular AMI, n (%)	12 (9.8)	215 (11.6)	0.52
Previous AMI, n (%)	32 (27.6)	376 (20.6)	0.05
Previous PCI, n (%)	30 (25.6)	295 (16.2)	0.008
Previous CABG, n (%)	9 (7.8)	76 (4.2)	0.06
Previous stroke, n (%)	12 (10.4)	117 (6.4)	0.08
Heart failure, n (%)	12 (10.4)	91 (5.0)	0.003
Chronic renal failure, n (%)	9 (7.8)	53 (2.9)	0.03
COPD, n (%)	11 (9.6)	84 (4.6)	0.02
Weight, kg	69.3 ± 13.2	77.3 ± 14.4	< 0.001
Height, m	64.2 ± 8.9	67.9 ± 8.5	< 0.001
Abdominal circumference, cm	94.2 ± 13.1	96.7 ± 13.9	0.09
SBP, mmHg	129.6 ± 31.9	136.9 ± 52.6	0.17
DBP, mmHg	74.5 ± 19.7	82.7 ± 18.6	< 0.001
Heart rate, bpm	79.3 ± 21.6	78.7 ± 19.8	0.76
Killip class 3 or 4, n (%)	16 (13.1)	137 (7.4)	0.02
Left bundle branch block, n (%)	5 (4.1)	19 (1.0)	0.003
TAVB, n (%)	8 (6.6)	48 (2.6)	0.01
Delta T, hour	3.7 [1.9-6.2]	3.9 [1.9-6.5]	0.77
Door-to-balloon time, hour	1.4 [1.0-1.9]	1.1 [0.8-1.5]	< 0.001
Previous use of ASA, %	49 (42.6)	513 (28.2)	< 0.001

CAD: coronary artery disease; AMI: acute myocardial infarction; PCI: percutaneous coronary angioplasty; CABG: coronary artery bypass grafting; COPD: chronic obstructive pulmonary disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; TAVB: total atrioventricular block; ASA: acetylsalicylic acid.

Table 2 Angiographic and procedure characteristics.

Characteristics	≥ 80 years	< 80 years	<i>p</i> -value
	(n = 122)	(n = 1,848)	
Femoral access, n (%)	98 (82.4)	1.151 (62.3)	< 0.001
6 F sheath, n (%)	113 (92.6)	1.680 (90.9)	0.74
Triple-vessel disease, n (%)	25 (20.5)	343 (18.6)	0.33
LMCA lesion, n (%)	7 (5.7)	62 (3.4)	0.16
LVEF, %	39.7 ± 18.5	54.5 ± 16.0	0.008
Bifurcation, n (%)	15 (12.3)	338 (18.3)	0.10
Thrombus, n (%)	75 (65.2)	1.259 (71.1)	0.17
Calcium, n (%)	35 (30.4)	208 (11.8)	< 0.001
Diameter stenosis pre, %	97.1 ± 6.0	97.0 ± 7.9	0.87
Lesion extension, mm	16.1 ± 6.6	18.4 ± 8.9	0.03
TIMI 0 pre, n (%)	79 (68.7)	1.206 (68.2)	0.72
Blush 0 pre, n (%)	86 (74.8)	1.354 (77.0)	0.44
Pre-dilation, n (%)	88 (76.5)	1.076 (60.3)	0.001
Thrombus aspiration, n (%)	31 (26.7)	544 (30.3)	0.41
Kissing-balloon, n (%)	4 (3.4)	67 (3.7)	0.87
Stent use, n (%)	101 (87.1)	1.604 (89.1)	0.49
Post-dilation, n (%)	32 (28.3)	488 (27.6)	0.86
Reference diameter, mm	3.01 ± 0.40	3.19 ± 0.80	0.03
Stent caliber, mm	3.36 ± 3.51	3.17 ± 0.48	0.59
Stent length, mm	19.1 ± 6.2	20.3 ± 6.5	0.08
Balloon caliber, mm	3.32 ± 0.37	3.44 ± 0.62	0.29
Maximum balloon pressure, atm	17.8 ± 4.0	17.4 ± 4.0	0.88
Final vessel diameter, mm	3.23 ± 0.44	3.37 ± 0.56	0.004
Diameter stenosis post, %	5.3 ± 20.8	4.2 ± 17.6	0.52
TIMI 3 post, n (%)	98 (86.0)	1.575 (90.7)	0.08
Blush 3 post, n (%)	67 (59.3)	1.222 (70.9)	0.01
Glycoprotein IIb/IIIa, n (%)	14 (11.9)	584 (32.2)	< 0.001
Clopidogrel 600 mg, n (%)	83 (70.3)	1.589 (87.4)	< 0.001
Intra-aortic balloon pump, n (%)	8 (6.7)	54 (3.0)	0.02
Angiographic success, n (%)	103 (92.0)	1.635 (95.6)	0.07

 $LMCA: left\ main\ coronary\ artery;\ LVEF: left\ ventricular\ ejection\ fraction;\ TIMI:\ Thrombolysis\ in\ Myocardial\ Infarction.$

Table 3 Laboratory characteristics

Characteristics	≥ 80 years	< 80 years	<i>p</i> -value
	(n = 122)	(n = 1,848)	
Total cholesterol, mg/dL	181.5 ± 50.0	205.5 ± 54.8	< 0.001
HDL, mg/dL	44.0 ± 13.7	41.6 ± 12.2	0.08
Triglycerides, mg/dL	121.7 ± 83.7	163.7 ± 212.7	0.06
Creatinine, mg/dL	1.2 ± 0.4	1.1 ± 4.2	0.77
ECC, mL/minute	43.4 ± 20.4	91.0 ± 38.3	< 0.001
Glycemia, mg/dL	174.2 ± 70.7	169.1 ± 84.5	0.56
Hematocrit, %	37.2 ± 4.6	41.0 ± 4.7	< 0.001
Hemoglobin, g/dL	12.2 ± 1.8	13.8 ± 1.6	< 0.001
Platelets, mil/mm ³	228,644 ± 68,477	249,418 ± 77,141	0.01
Leukocytes, mil/mm³	12,270 ± 8,664	13,065 ± 6,005	0.20
Potassium, mEq/L	4.5 ± 0.6	4.6 ± 10.2	0.93
Magnesium, mEq/L	2.2 ± 0.4	2.2 ± 0.6	0.52
HbA1c, %	5.9 [5.7-6.3]	5.7 [5.4-6.5]	0.31
Total CK, UI/L	88.0 [41.0-309]	139.5 [60-423]	0.17
Peak CK-MB, UI/L	43.0 [16.7-83.7]	40.5 [17.0-81.0]	0.66
Peak hsTnT, UI/L	2,776 [712-7,853]	2,417 [641-5,915]	0.10
CRP, g/dL	0.3 [0.1-1.2]	0.4 [0.2-0.9]	0.77
Fibrinogênio, mg/dL	247.4 ± 72.2	255.8 ± 89.4	0.43

HDL: high density lipoprotein; ECC: endogenous creatinine clearance; HbA1c: glycated hemoglobin; CK: creatine kinase; CK-MB: creatine kinase MB isoenzyme; hsTnT: highsensitivity troponin T; CRP: C-reactive protein.

Table 4Complications and clinical outcomes at 30 days

Complications	≥ 80 years (n = 122)	< 80 years (n = 1,848)	<i>p</i> -value
Death, n (%)	35 (29.7)	132 (7.2)	< 0.001
Ischemic stroke, n (%)	1 (0.9)	4 (0.2)	0.27
Reinfarction, n (%)	5 (4.3)	77 (4.2)	0.55
MACE, n (%)	38 (32.2)	211 (11.5)	< 0.001
Stent thrombosis, n (%)	2 (1.7)	43 (2.4)	0.48

MACE: major adverse cardiovascular events.

The presence of a greater number of comorbidities in this group was observed in this cohort and may justify such unfavorable evolution.¹ Previous heart failure, diabetes, CKD, pulmonary disease, and previous AMI were more prevalent in very elderly patients. Additionally, antiplatelet agents were less commonly used in these patients. Previous studies showed an association between advanced age and poor evolution regardless of the reperfusion strategy. In addition to the identified factors associated with increased risk, other non-measurable aspects, such as fragility and homeostatic reserve, may contribute to a poor outcome.⁶ In a previous registry, age > 85 years, but not age > 75 years, was an independent predictor of mortality at 30 days.¹³

The estimated total ischemic time was longer, due to the greater delay in the door-to-balloon time in the group aged \geq 80 years. Difficulties in the diagnosis or treatment of complications at presentation can be determinant factors of intervention delay. As previously acknowledged, there is a strong association between delayed care and mortality. 10,13

Signs of severe ventricular dysfunction (Killip 3 or 4) at presentation were more frequent in the group aged ≥ 80 years. This factor is associated with worse in-hospital evolution in AMI.¹¹ Similarly, advanced conduction disorders occurred more commonly in this age group and may be associated with worse prognosis. Earlier diagnosis and treatment could reduce the rate of patients with hemodynamic impairment.

CKD is one of the main factors associated with a poorer outcome in AMI. It is known that CKD is associated with coagulation disorders and higher rates of bleeding and thrombosis, in addition to more calcified lesions.

The preferred vascular access in the elderly was the femoral route. During the analyzed period, the femoral access was still preferred in urgency situations in Brazil. More recently, there has been a reversal in

the utilization rates of the radial access, as lower rates of complications and mortality have been demonstrated. Patients at a very advanced age may present more complex radial artery anatomy, such as marked tortuosity, vascular calcification, and small-vessel caliber. However, the learning curve with the technique has allowed greater success with a lower rate of vascular complications.¹⁴

Study limitations

This was an observational study; conclusions about the effect of therapies on outcomes may have been affected by confusion bias. Angiographic analysis was not independently assessed by a distinct angiographic laboratory, a limitation that is also shared by other studies of patients with primary coronary angioplasty. Finally, the long-term follow-up of these patients is not yet available, but short-term outcomes are known to be important and reliable in assessing the outcomes of patients with AMI.

Conclusions

In this contemporary analysis, patients aged ≥ 80 years submitted to primary percutaneous coronary intervention had a more severe clinical and angiographic profile, longer door-to-balloon time, lower final Blush 3, and higher rates of in-hospital complications and 30-day mortality when compared with younger patients.

With the aging of the population, the care of these patients with acute myocardial infarction should progressively increase, as well as the use of interventional strategies and antiplatelet therapy, imposing the need for improvements in the diagnosis and treatment of these patients, aiming to improve outcomes for this population group.

Funding sources

None.

Conflicts of interest

The authors declare no conflicts of interest.

References

- Claussen PA, Abdelnoor M, Kvakkestad KM, Eritsland J, Halvorsen S. Prevalence of risk factors at presentation and early mortality in patients aged 80 years or older with ST-segment elevation myocardial infarction. Vasc Health Risk Manag. 2014;10:683-9.
- Medina HM, Cannon CP, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Frank Peacock W, et al.; GWTG Steering Committee and Investigators. Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelinescoronary artery disease. Clin Cardiol. 2012;35(10):632-40.
- 3. Gao L, Hu X, Liu YQ, Xue Q, Feng QZ. Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction. Clin Interv Aging. 2014;9:1241-6.
- Wennberg DE, Makenka DJ, Sengupta A, Lucas FL, Vaitkus PT, Quinton H, et al. Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes. The Northern New England Cardiovascular Disease Study Group. Am Heart J. 1999;137(4 Pt 1):639-45.
- Kvakkestad KM, Abdelnoor M, Claussen PA, Eritsland J, Fossum E, Halvorsen S. Long-term survival in octogenarians and older patients with ST-elevation myocardial infarction in the era of primary angioplasty: a prospective cohort study. Eur Heart J Acute Cardiovasc Care. 2016;5(3):243-52.
- Ariza-Solé A, Formiga F, Vidán MT, Bueno H, Curós A, Aboal J, et al. Impact of frailty and functional status on outcomes in elderly patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: rationale and design of the IFFANIAM study. Clin Cardiol. 2013;36(10):565-9.

- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/ AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122.
- 8. Caretta G, Passamonti E, Pedroni PN, Fadin BM, Galeazzi GL, Pirelli S. Outcomes and predictors of mortality among octogenarians and older with ST-segment elevation myocardial infarction treated with primary coronary angioplasty. Clin Cardiol. 2014;37(9):523-9.
- 9. Azmus AD, Gottschall CA, Gus M. [Analysis of primary angioplasty in the treatment of acute myocardial infarction hospitalar and long term results]. Revista AMRIGS. 2003;47(1):38-45. Portuguese.
- 10. Newell MC, Henry TD. Primary PCI in the elderly: 75 may be the new 55! Catheter Cardiovasc Interv. 2012;79(1):57-8.
- Lee KH, Ahn Y, Kim SS, Rhew SH, Jeong YW, Jang SY, et al.; KAMIR (Korea Acute Myocardial Infarction Registry) Investigators. Characteristics, in-hospital and long-term clinical outcomes of nonagenarian compared with octogenarian acute myocardial infarction patients. J Korean Med Sci. 2014;29(4):527-35.
- 12. Gharacholou SM, Lopes RD, Alexander KP, Mehta RH, Stebbins AL, Pieper KS, et al. Age and outcomes in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: findings from the APEX-AMI trial. Arch Intern Med. 2011;171(6):559-67.
- 13. Sakai K, Nagayama S, Ihara K, Ando K, Shirai S, Kondo K, et al. Primary percutaneous coronary intervention for acute myocardial infarction in the elderly aged ≥75 years. Catheter Cardiovasc Interv. 2012;79(1):50-6.
- 14. Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, et al.; European Association of Percutaneous Cardiovascular Interventions; Working Group on Acute Cardiac Care of the European Society of Cardiology; Working Group on Thrombosis on the European Society of Cardiology. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention. 2013;8(11):1242-51.